Edition:
United States

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

186.92USD
20 Feb 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$186.92
Open
$187.19
Day's High
$189.22
Day's Low
$186.48
Volume
3,046,393
Avg. Vol
3,191,408
52-wk High
$210.19
52-wk Low
$163.31

Chart for

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.20
Market Cap(Mil.): $116,347.30
Shares Outstanding(Mil.): 622.28
Dividend: 1.45
Yield (%): 2.89

Financials

  AMGN.O Industry Sector
P/E (TTM): 14.84 32.66 36.18
EPS (TTM): 12.60 -- --
ROI: 13.55 13.07 12.67
ROE: 44.48 14.08 13.70

PTAB sides with Sanofi in Dupixent fight with Amgen

The Patent Trial and Appeal Board on Thursday invalidated all claims of a patent that Amgen has accused Sanofi-Aventis and Regeneron Pharmaceuticals of infringing with their breakthrough biologic Dupixent.

Feb 15 2019

Judge bars Amgen’s willfulness claims in retrial of cholesterol-drug patent lawsuit

Amgen Inc cannot claim that Sanofi SA and Regeneron Pharmaceuticals willfully infringed its patents on the cholesterol-lowering drug Repatha when the case is retried this month, a federal judge in Delaware ruled on Friday.

Feb 11 2019

Sanofi and Regeneron cut list price of cholesterol drug by 60 percent

NEW YORK Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug.

Feb 11 2019

Sanofi and Regeneron cut list price of cholesterol drug by 60 pct

NEW YORK, Feb 11 Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug.

Feb 11 2019

Amgen 2019 forecast falls short of expectations, shares dip

Amgen Inc on Tuesday reported fourth-quarter profit that easily surpassed expectations as sales rose and tax expense fell, but competition for its older medicines is growing and the drugmaker forecast 2019 earnings below Wall Street estimates.

Jan 29 2019

UPDATE 2-Amgen 2019 forecast falls short of expectations, shares dip

Jan 29 Amgen Inc on Tuesday reported fourth-quarter profit that easily surpassed expectations as sales rose and tax expense fell, but competition for its older medicines is growing and the drugmaker forecast 2019 earnings below Wall Street estimates.

Jan 29 2019

Amgen quarterly profit tops Street view, 2019 forecast falls short

Jan 29 Amgen Inc on Tuesday reported higher-than-expected fourth-quarter profit as sales rose and tax expense fell, but competition for older medicines is growing and the drugmaker forecast 2019 earnings below Wall Street estimates.

Jan 29 2019

Amgen's postmenopausal osteoporosis drug wins FDA panel backing

An advisory panel to the U.S. Food and Drug Administration said on Wednesday that benefits of Amgen Inc's osteoporosis treatment for postmenopausal women at high risk for fracture outweighed its risks and overwhelmingly voted for the drug's approval.

Jan 16 2019

UPDATE 2-Amgen's postmenopausal osteoporosis drug wins FDA panel backing

Jan 16 An advisory panel to the U.S. Food and Drug Administration said on Wednesday that benefits of Amgen Inc's osteoporosis treatment for postmenopausal women at high risk for fracture outweighed its risks and overwhelmingly voted for the drug's approval.

Jan 16 2019

Amgen's postmenopausal osteoporosis drug wins FDA panel backing

Jan 16 An advisory panel to the U.S. Food and Drug Administration on Wednesday recommended Amgen Inc's osteoporosis treatment for postmenopausal women at high risk for fracture, saying the benefits of the drug outweighed its risks.

Jan 16 2019

Earnings vs. Estimates